Physician profile
Justin Ranes
NPI 1932182532
$8,210.89
in general payments reported to CMS, 2019-2025
37 companies · $4,481 in 2025
The $4,481 reported for 2025 was more than what 87% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $754 · 2020: $458 · 2021: $572 · 2022: $566 · 2023: $686 · 2024: $694 · 2025: $4,481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,000 · Food and Beverage: $1,842 · Travel and Lodging: $1,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,000.00 |
| Food and Beverage | $1,841.99 |
| Travel and Lodging | $1,018.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,018.92 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $589.98 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $586.04 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $318.41 | 2019-2024 | Ofev |
| Abbvie INC. | $250.19 | 2021-2024 | |
| Jazz Pharmaceuticals INC. | $221.76 | 2019-2025 | |
| Genzyme Corporation | $201.64 | 2019-2024 | |
| Electromed, INC. | $160.47 | 2019-2023 | Smartvest |
| Merck Sharp & Dohme LLC | $153.10 | 2019-2024 | Dificid, Zerbaxa, Recarbrio |
| Harmony Biosciences LLC | $141.25 | 2021-2025 | |
| Mylan Specialty L.P. | $132.21 | 2022-2024 | Yupelri |
| Insmed, INC. | $131.40 | 2019-2025 | Arikayce |
| Grifols USA, LLC | $123.84 | 2019-2024 | Prolastin-C Liquid |
| Genentech USA, INC. | $121.57 | 2019-2025 | Xolair |
| United Therapeutics Corporation | $114.38 | 2021-2025 | Tyvaso, Tyvaso |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Ranes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.